One of the best con­nect­ed biotech star­tups in Boston snags a plum dis­cov­ery deal with No­var­tis

No­var­tis’ drug dis­cov­ery crew in­side the NI­BR cam­pus in Cam­bridge, MA is putting $30 mil­lion on the ta­ble to get a new TCR im­muno-on­col­o­gy pro­gram kicked off with one of the re­cent star­tups to de­but in the field — se­ri­ous mon­ey for what they be­lieve can of­fer an ef­fec­tive ap­proach to tack­ling sol­id tu­mors.

Christoph West­phal’s lat­est biotech cre­ation, TScan, lined up the deal, which drew in a No­var­tis crew at­tract­ed by their ap­proach in de­vel­op­ing TCR-en­gi­neered T cell ther­a­pies.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER